Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Four-in-One antibody takes on Hard-to-Treat blood cancers

NCT ID NCT05104775

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times

Summary

This early-phase study tests a new drug called GNC-035 in 33 adults with blood cancers that have come back or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The drug is a special antibody designed to attack cancer cells in multiple ways.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Affiliated Hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Guangzhou First People's Hospital

    Guangzhou, Guangdong, China

  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, 200025, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • The Second People's Hospital of Yibin

    Yibin, Sichuang, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, Hubei, China

Conditions

Explore the condition pages connected to this study.